Home Newsfeeds Athira Pharma Q2 EPS $(0.65) Down From $(0.38) YoY

Athira Pharma Q2 EPS $(0.65) Down From $(0.38) YoY

Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.65) per share. This is a 71.05 percent decrease over losses of $(0.38) per share from the same period last year.

byBenzinga Newsdesk

August 15, 2022

1 minute read

Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.65) per share. This is a 71.05 percent decrease over losses of $(0.38) per share from the same period last year.

US Government Fights To Keep Former Binance CEO Changpeng Zhao On American Soil

By Mehab Qureshi

November 23, 3:01 AM

Prosecutors are fervently advocating for former Binance head Changpeng “CZ” Zhao to remain in the United States, expressing apprehensions about his possible flight risk.

BTC

News

‘Biden To Pardon All Federal Offenses Of Simple Marijuana Possession In First Major Steps Toward Decriminalization’ – CNN

By Benzinga Newsdesk

October 6, 3:37 PM

https://www.cnn.com/2022/10/06/politics/marijuana-decriminalization-white-house-joe-biden/index.html President Joe Biden is taking his first major steps toward decriminalizing marijuana, fulfilling a campaign

ACB

Lixte Biotechnology Holdings Announces The Passing Of Its Founder And Executive Chairman, John S. Kovach

By Benzinga Newsdesk

October 9, 8:38 AM

LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced the passing of its

LIXT